Repurposing gestrinone for tumor suppressor through P21 reduction regulated by JNK in gynecological cancer

Huai-How Ciou, Tsung-Hsien Lee, Lee TH, Hsin-Chieh Wang, Wang HC, Ding YR, You-Ren Ding, Chih-Jen Tseng, Tseng CJ, Po-Hui Wang, Wang PH, Meng-Hsiun Tsai, Tsai MH, Shu-Ling Tzeng, Tzeng SL
Translational research : the journal of laboratory and clinical medicine · 2022 · vol. 243 , pp. 21–32 · doi:10.1016/j.trsl.2021.12.002 · PMID:34921996
Observational OA: hybrid CC-BY-NC-ND-4.0
🔓 Open OA copy View on PubMed View at publisher
⚙ AI-generated summary by gemini-2.5-flash-lite, 2026-06-07 ⓘ

Gestrinone, a drug for endometriosis, was found to reduce gynecological cancer risk by inhibiting cervical cancer cell growth through JNK-mediated P21 reduction and apoptosis induction.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

Abstract

Endometriosis has been shown to increase the risk of gynecological cancers. However, the effect of gestrinone, a clinical endometriosis drug, on gynecological cancers remains unclear. This study aimed to understand the effect of gestrinone on gynecological cancers. A retrospective study was conducted using the Longitudinal Health Insurance Database 2000 of the Taiwan National Health Insurance Research Database (NHIRD) to observe the risk of gynecological cancers. Medication records from the Department of Obstetrics and Gynecology, Chung Shan Medical University Hospital CSMUH and cancer records from the Taiwan Cancer Registry were collected to analyze the correlation between gestrinone use and gynecological cancers. Subsequently, human cell lines were used to investigate the effect of gestrinone on gynecological cancers. A total of 8330 endometriosis patients were enrolled, and analyses revealed that endometriosis patients had a higher risk of developing ovarian and endometrial cancer. However, the rate of cervical cancer was not statistically different (P = 0.249). Analyses of both the NHIRD and CSMUH databases revealed that gestrinone may reduce the risk of gynecological cancer. Cellular experiments verified the anticancer effects of gestrinone, which effectively and specifically inhibited the growth of HeLa cervical cancer cells, decreased P21 expression via JNK phosphorylation, and induced apoptosis. Combining the results of clinical database analysis and cell experiments, our findings prove that gestrinone has the potential to protect against cancer through regulation of the JNK-P21 axis. Repurposing the anticancer efficacy of gestrinone may be a strategy for targeted therapy in the future.

My notes (saved in your browser only)

Condition tags

endometriosis

MeSH descriptors

Endometriosis Endometriosis Gynecology Gynecology Neoplasms Neoplasms Neoplasms Drug Repositioning Drug Repositioning Female Female Gestrinone Gestrinone Gestrinone Humans Humans Pregnancy Pregnancy Retrospective Studies Retrospective Studies

Funding

funders
[{'doi': '10.13039/501100004699', 'name': 'Chung Shan Medical University Hospital', 'awards': []}, {'doi': '10.13039/501100004737', 'name': 'National Health Research Institutes', 'awards': ['NHIRD-104-367']}, {'doi': '10.13039/501100008641', 'name': 'Chung Shan Medical University', 'awards': ['NCHU-CSMU-10513']}, {'doi': '10.13039/501100008641', 'name': 'Chung Shan Medical University', 'awards': ['NCHU-CSMU-10608']}, {'doi': '10.13039/100008903', 'name': 'Ministry of Health and Welfare', 'awards': []}, {'doi': '10.13039/501100001868', 'name': 'National Science Council', 'awards': []}, {'doi': '10.13039/100014477', 'name': 'National Health Insurance Administration', 'awards': []}]

Citation neighborhood (2-hop)

Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. Outer rings show 2-hop neighbours — papers reached through the immediate citers/citees. [ collapse to 1-hop ]

References (35)

Source provenance

crossref
last seen: 2026-05-22T01:00:27.360627+00:00
europepmc
last seen: 2026-10-12T06:17:10.165071+00:00
pubmed
last seen: 2026-10-08T21:33:28.679823+00:00
unpaywall
last seen: 2026-05-14T19:30:52.867331+00:00
License: CC-BY-NC-ND-4.0 · commercial use OK · attribution required
Courtesy of the U.S. National Library of Medicine